CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $260,766 | -18.6% | 5,745 | +0.7% | 0.00% | -33.3% |
| Q2 2023 | $320,391 | -13.9% | 5,707 | -30.6% | 0.00% | 0.0% |
| Q1 2023 | $372,030 | +6.4% | 8,226 | -4.3% | 0.00% | 0.0% |
| Q4 2022 | $349,590 | -19.4% | 8,600 | +29.5% | 0.00% | -66.7% |
| Q3 2022 | $434,000 | -11.4% | 6,643 | -17.6% | 0.01% | +12.5% |
| Q2 2022 | $490,000 | -0.2% | 8,064 | +3.0% | 0.01% | +14.3% |
| Q1 2022 | $491,000 | -7.0% | 7,827 | +12.4% | 0.01% | -12.5% |
| Q4 2021 | $528,000 | -34.7% | 6,964 | -3.5% | 0.01% | -38.5% |
| Q3 2021 | $808,000 | -22.1% | 7,217 | +12.6% | 0.01% | -23.5% |
| Q2 2021 | $1,037,000 | +84.2% | 6,408 | +38.6% | 0.02% | +54.5% |
| Q1 2021 | $563,000 | -28.1% | 4,622 | -9.6% | 0.01% | -26.7% |
| Q4 2020 | $783,000 | – | 5,111 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |